| P50 | author | Eric Q. Konnick | Q51740671 |
| | Ahmed Diab | Q61161465 |
| | R Alex Harbison | Q81891332 |
| P2093 | author name string | Laura Q M Chow | |
| | Eduardo Méndez | |
| | Neal D Futran | |
| | Renato Martins | |
| | Rafael Santana-Davila | |
| | Sharat Raju | |
| | Cristina P Rodriguez | |
| | Ganesh M Mugundu | |
| | Michael C Kao | |
| P2860 | cites work | MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells | Q39442905 |
| | Applying Ancestry and Sex Computation as a Quality Control Tool in Targeted Next-Generation Sequencing | Q39813483 |
| | Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens | Q41906700 |
| | MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil | Q43182482 |
| | Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. | Q45152760 |
| | Microsatellite instability detection by next generation sequencing | Q45790131 |
| | Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies | Q46441349 |
| | Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775. | Q50207725 |
| | Cyclins A and E trigger DNA damage | Q60635068 |
| | Is there a new role for induction chemotherapy in the treatment of head and neck cancer? | Q81015149 |
| | ATM and ATR signaling at a glance | Q26777159 |
| | Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 |
| | Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 | Q29614651 |
| | The mutational landscape of head and neck squamous cell carcinoma | Q29614654 |
| | TP53 mutations and survival in squamous-cell carcinoma of the head and neck. | Q30366618 |
| | Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. | Q30591228 |
| | Functional kinomics identifies candidate therapeutic targets in head and neck cancer | Q34055936 |
| | Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial | Q34328071 |
| | Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer | Q34430205 |
| | Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence | Q36020559 |
| | Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors | Q36162494 |
| | Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins | Q36244669 |
| | Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1 | Q36956909 |
| | Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease | Q38256335 |
| | Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors | Q38378490 |
| | Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy | Q39148462 |
| | Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. | Q39294122 |
| | Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. | Q39342402 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | docetaxel | Q420436 |
| | phase I clinical trial | Q5452194 |
| | cisplatin | Q412415 |
| P304 | page(s) | 2740-2748 | |
| P577 | publication date | 2018-03-13 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. | |
| P478 | volume | 24 | |